Incyte Corp INCYTE ORD SHS
Incyte Corp INCYTE ORD SHS/ US45337C1027 /
0J9P
|
04/01/2024 00:00:00
|
Chg.
-
|
Volume |
Bid06:00:04 |
Ask06:00:04 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
65.51USD
|
-
|
47
Turnover: - |
-Bid Size: - |
-Ask Size: - |
16.06 bill.USD |
- |
31.23 |
Business description
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Management board & Supervisory board
| CEO |
| Hervé Hoppenot |
| Management board |
| Christiana Stamoulis, Paula J. Swain, Pablo J. Cagnoni, Steven H. Stein, M.D., Maria E. Pasquale, Dr. Lothar H. Finke, Barry P. Flannelly, Denise Brashear, Vijay Iyengar, M.D., Jonathan E. Dickinson, Michael Morrissey, Xiaozhao Wang |
| Supervisory board |
| Hervé Hoppenot, Julian C. Baker, Jean-Jacques Bienaimé, Otis Brawley, M.D., Paul J. Clancy, Dr. Jacqualyn A. Fouse, Edmund P. Harrigan, M.D., Katherine High, M.D., Susanne Schaffert |
Company data
| Name: |
Incyte Corporation |
| Address: |
1801 Augustine Cut-Off,Wilmington, DE 19803, USA |
| Phone: |
+1-302-498-6700 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.incyte.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
31/12 |
| Free Float: |
41.80% |
| IPO date: |
- |
Investor relations
| Name: |
Ben Strain |
| IR phone: |
+1-302-274-4779 |
| IR Fax: |
- |
| IR e-mail: |
IR@incyte.com
|
